Brief: MEI Pharma Says It Will Not Proceed With Second Capital Return Under 2023 Anson And Cable Car Cooperation Agreement
11/04/2024 15:23
April 11 (Reuters) - MEI Pharma Inc MEIP.O :
* MEI PHARMA INC - NOT TO PROCEED WITH SECOND CAPITAL RETURN
UNDER
2023 ANSON AND CABLE CAR COOPERATION AGREEMENT
* MEI PHARMA BOARD OF DIRECTORS ALIGNS ON STRATEGY TO
ADVANCE
VORUCICLIB AND ME-344
* MEI PHARMA INC - BOARD OF DIRECTORS UNANIMOUSLY AGREED ON
A
STRATEGIC PLAN TO LEVERAGE RECENT POSITIVE VORUCICLIB AND ME-344
CLINICAL DATA
* MEI PHARMA INC: TO PRIORITIZE CLINICAL DEVELOPMENT OF
VORUCICLIB
WHILE ENABLING DEVELOPMENT OF A NEW ME-344 FORMULATION FOR PHASE
1 STUDY
* MEI PHARMA INC: PLAN WILL REDUCE SHORT-TERM EXPENDITURES
ON
ME-344 PROGRAM
Source text for Eikon: ID:nBw6rz4Gma
Further company coverage: MEIP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations